Rare Tumour Group

Mission Statement

 

  • We aim to accelerate the development of new therapies derived from a solid scientific rational for women with rare gynaecological cancer through European collaboration.

  • We aim at using the multidisciplinary expertise available within ENGOT to develop trials covering an area of clear unmet need.

  • We aim at strengthening the scientific basis including in these initiative, a strong collaboration with the translational group, and biobanking activities.

 

Objectives

 

  • To develop a network of collaborations among centers and investigators within ENGOT to design clinical trials with strong scientific rational in rare gynaecological cancer.

  • To develop novel trial designs that allow efficient assessment of new compounds and make it feasible to also investigate rare histological and molecular subtypes.

  • To offer pharmaceutical companies a read-to-go, efficient structure and academic expertise for accelerated clinical development of their compounds in their pipeline.

  • To involve all the groups in this strategic plan that will allow ENGOT to promote a significant gain in the clinical outcomes of many rare tumours.

 

Next ENGOT Rare Tumour Group Meeting

Frankfurt, Germany, May 9, 2018

You May Also Like

GCA6

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

background

CLINICAL TRIALS

Latest Published Research

 

Read More

patient2

FOR PATIENTS

Key Insights

 

Read More

Untitled design (19)

ESGO 2018

State of the Art Conference

 

Read More